Skip to main
  1. Stocks
  2. Zymeworks Inc
  3. Forecast
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is viewed favorably because its model now combines partner-funded development, recurring royalties, and commercial cash flow, reducing capital intensity while preserving upside from pipeline expansion. The FDA approval of Ziihera in 1L HER2-positive GEA, alongside HERIZON-GEA-01 data showing median PFS of 12.4 months versus 8.1 months and median OS of 26.4 months versus 19.2 months, materially de-risks the core asset and supports meaningful future royalty revenue. Additional support comes from a solid cash position of $572.5MM pro-forma, a $250M milestone payment, and advancing wholly owned programs such as ZW191 and ZW251.

Bears say

Zymeworks is viewed negatively because the bear case assumes zanidatamab’s commercial launch is underwhelming, which sharply reduces expected monetization from global royalties and milestones in BTC and GEA and eliminates any platform value. The company remains highly exposed to core biotech risks: clinical development failure, intense competition from existing and emerging therapies, and regulatory dependence on the FDA’s review pace and approval decisions. With a lower 10% probability of success in the royalty and milestone stream and a valuation framework that already supports only $15 fair value, the stock appears vulnerable to further downside if the program fails to deliver differentiated data or market traction.

Zymeworks Inc (ZYME) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction

Get the latest Zymeworks Inc (ZYME) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Zymeworks Inc (ZYME)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 11 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction

Get the latest Zymeworks Inc (ZYME) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Zymeworks Inc (ZYME)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ZYME stock data and trends